Current Report Filing (8-k)
22 April 2020 - 10:36PM
Edgar (US Regulatory)
false
0000773141
0000773141
2020-04-20
2020-04-20
0000773141
mdc:CommonStock01ParValueCustomMember
2020-04-20
2020-04-20
0000773141
mdc:SeniorNotesDueJanuary20436CustomMember
2020-04-20
2020-04-20
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): April 20, 2020
MDC Holdings, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
1-8951
|
84-0622967
|
|
(State or other
|
(Commission file number)
|
(I.R.S. employer
|
|
jurisdiction of
|
|
identification no.)
|
|
incorporation)
|
|
|
4350 South Monaco Street, Suite 500, Denver, Colorado 80237
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: (303) 773-1100
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, $.01 par value
|
|
552676108
|
|
New York Stock Exchange
|
|
6% Senior Notes due January 2043
|
|
552676AQ1
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
ITEM 1.01
|
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
|
M.D.C. Holdings, Inc. 2020 Equity Plan for Non-Employee Directors
On April 20, 2020, M.D.C. Holdings, Inc. (the "Company") held its 2020 Annual Meeting of Shareholders (the “2020 Annual Meeting”) at which the Company’s shareholders approved an amendment and restatement of the M.D.C. Holdings, Inc. 2011 Stock Option Plan for Non-Employee Directors renamed as the M.D.C. Holdings, Inc. 2020 Equity Plan for Non-Employee Directors (the “2020 Director Equity Plan”). The 2020 Director Equity Plan had been previously recommended for approval by the Company’s Compensation Committee of the Board of Directors and previously approved by the Company’s Board of Directors, in each case, subject to shareholder approval. The 2020 Director Equity Plan became effective as of the date of such shareholder approval – April 20, 2020.
In addition to the plan being renamed, the 2020 Director Equity Plan, among other things, increased the number of shares covered by the annual grant of each stock option (without increasing the total number of shares authorized under the plan) to reflect, on a going forward basis, the three stock dividends since the first effective date of the plan.
The material features of the 2020 Director Equity Plan are described in the section entitled “Proposal Three - Approval of Amendment and Restatement of the M.D.C. Holdings, Inc. 2020 Equity Plan for Non-Employee Directors” appearing on pages 61-68 of the Company’s definitive Proxy Statement on Schedule 14A filed on February 25, 2020 in connection with the 2020 Annual Meeting, which description is incorporated herein by reference. A copy of the 2020 Directory Equity Plan, as restated, is filed as Exhibit 10.1 hereto and incorporated herein by reference.
|
ITEM 5.07
|
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
On April 20, 2020, the Company held its 2020 Annual Meeting. There were 63,052,543 shares of common stock entitled to vote at the meeting. The final voting results for each of the proposals submitted to a vote of shareholders at the 2020 Annual Meeting were as follows:
|
|
(1)
|
Election of three Class II Directors of the Company to serve for three-year terms expiring in 2023:
|
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
|
David D. Mandarich
|
51,783,317
|
|
2,983,769
|
|
3,071,182
|
|
Paris G. Reece III
|
42,048,614
|
|
12,718,472
|
|
3,071,182
|
|
David Siegel
|
42,360,189
|
|
12,406,897
|
|
3,071,182
|
|
|
(2)
|
Approval, in a non-binding advisory vote, of the compensation of the Company’s named executive officers:
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
|
41,028,619
|
|
11,780,573
|
|
1,957,894
|
|
3,071,182
|
|
|
(3)
|
Approval of the amended and restated 2020 Director Equity Plan:
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
|
52,039,560
|
|
2,679,649
|
|
47,877
|
|
3,071,182
|
|
|
(4)
|
Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the 2020 fiscal year:
|
|
For
|
|
Against
|
|
Abstain
|
|
|
|
56,979,036
|
|
823,703
|
|
35,529
|
|
|
|
ITEM 9.01.
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
M.D.C. HOLDINGS, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
Dated: April 22, 2020
|
By:
|
/s/ Joseph H. Fretz
|
|
|
|
|
Joseph H. Fretz
|
|
|
|
|
Secretary and Corporate Counsel
|
|
M D C (NYSE:MDC)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
M D C (NYSE:MDC)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
